Pregabalin Capsule
Product Images NDC 71205-556

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-556-30 (Pregabalin Caps 50mg 30s Count)

Packaging label for Pregabalin 50 mg capsules by Proficient Rx LP. The label indicates 30 capsules per bottle with each capsule containing 50 mg of pregabalin. It includes identifying text on capsule appearance and storage instructions at 25°C (77°F). The label shows the NDC 71205-556-30 and manufacturer as ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day, as well as a placebo group. The graph compares the effectiveness of different Pregabalin dosages in improving patient pain symptoms.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A Kaplan-Meier type graph showing the percent of patients improved relative to percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day to placebo, with two vertical lines marking specific improvement thresholds.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline for Pregabalin capsules. The graph compares Pregabalin doses of 75 mg, 150 mg, and 300 mg taken two times a day against placebo, showing varying levels of patient improvement with increasing dose.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating their effectiveness in pain improvement.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line chart comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin 50 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The chart shows trends of patient improvement across these treatment regimens.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) between placebo and different dosages of pregabalin in two studies, Study E1 and Study E3. Study E1 shows increasing responder rates from placebo to 600 mg/day dosages, with doses given twice daily (BID). Study E3 shows responder rates for placebo, 300 mg/day (BID), and 600 mg/day (three times daily, TID) doses. Statistically significant differences versus placebo are marked.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day, comparing four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. The graph highlights statistically significant p-values for dose-dependent effects on seizure reduction.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline with different doses of Pregabalin (800 mg, 450 mg, and 300 mg daily) compared to placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved. Four lines depict the treatment groups: highest dose, two lower doses, and placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A survival curve chart comparing Pregabalin and placebo over 180 days. The y-axis shows estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group (solid line) shows higher percentages without LTR over time compared to the placebo group (dashed line).*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to week 12 for Pregabalin versus Placebo. The x-axis represents percent improvement from baseline, and the y-axis represents the percent of subjects improved. Two lines show higher improvement rates for Pregabalin compared to Placebo across the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 16 BOCF between Pregabalin and Placebo groups. The graph plots percent improved on the vertical axis and percent improvement from baseline on the horizontal axis, with Pregabalin showing consistently higher improvement rates than Placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for estimating creatinine clearance (CLcr) based on age, weight, and serum creatinine, including an adjustment factor of 0.85 for female patients. The formula is presented in a mathematical fraction format.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of the active ingredient pregabalin, showing its molecular configuration including an amino group (NH2) and a carboxylic acid group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.